Healthcare ratings roundup - new coverage

• StemCells (STEM -0.7%) initiated with Buy rating and $1 (67% upside) price target by H.C. Wainwright.
• Biodel (BIOD -0.9%) initiated with Buy rating and $5 (339% upside) price target by Roth Capital.
• Antares Pharma (ATRS -0.2%) initiated with Overweight rating and $3.50 (64% upside) price target by Piper Jaffray.
• Pfenex (PFNX -3.8%) initiated with Overweight rating and $28 (83% upside) price target by Barclays.